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Introduction {#sec005}
============

About two thirds of patients with squamous cell carcinomas of the head and neck (SCCHN) present with advanced disease (Stage III/IV). About 50% of SCCHN sustain local recurrence and up to 25% develop distant metastases \[[@pone.0132901.ref001], [@pone.0132901.ref002]\]. All of this results in a relatively poor prognosis with a 5-year survival rate of approximately 50%. One of the important risk factors is detected or occult lymph node metastasis in the neck. In order for SCCHN to spread other than by direct extension from its primary site in the head and neck to regional lymph nodes, the tumor must gain access to lymphovascular channels \[[@pone.0132901.ref003]\]. During this process tumor cells seem to detach from their primary tumor and enter the peripheral circulation. These cells are designated circulating tumor cells (CTCs) and are able to deposit within lymph nodes and other organs where they may proliferate and develop into eventual metastatic tumors. A CTCs is an epithelial derived, nucleated, often cytokeratin-positive cell that is not a normal constituent of blood, and cannot be identified in patients without an epithelial malignancy \[[@pone.0132901.ref004]\]. The clinical relevance of CTCs detection in carcinoma patients has been part of extensive research, and encouraging results exist for an association between CTCs detection and the prognosis in patients with other solid tumors, such as metastatic breast, prostate, and gastrointestinal cancers \[[@pone.0132901.ref005]--[@pone.0132901.ref007]\]. In SCCHN patients CTCs might potentially serve as a marker for nodal/metastatic disease, for assessing treatment susceptibility, for post-treatment cancer surveillance, and for prognosis \[[@pone.0132901.ref003]\].

Induction chemotherapy (IC) is one established strategy to reduce the risk of recurrence. IC has regained interest in SCCHN by two hallmark phase III trials using docetaxel, cisplatinum and 5-fluorouracil (TPF) as IC in locally advanced SCCHN prior to radiotherapy \[[@pone.0132901.ref008]\]. Recently we could show in a phase I trial that TPF is also feasible prior to surgery of locally advanced oral squamous cell cancer (OSCC)\[[@pone.0132901.ref009]\]. Meanwhile, this setting was also proven in a phase III trial \[[@pone.0132901.ref010]\]. OSCC represent about more than half of all SCCHN \[[@pone.0132901.ref011]\]. The value of CTCs in an IC setting to treat OSCC remains undetermined. The primary aim of this prospective study was therefore to establish the prognostic role of CTCs in advanced non-metastatic OSCC treated by IC before surgery and postoperative radiotherapy.

Materials and Methods {#sec006}
=====================

This translational study was part of an ongoing prospective multicenter phase II clinical trial (TISOC-1) conducted at six institutions in Germany (ClinicalTrials.gov; NCT01108042; 72 patients included; last patient in: August 2013; last patient out: December 2015). The first 50 patients took place in this translational study. The per-protocol follow-up of the 50^th^ patient ended in January 2014. Therefore, it was possible to report the outcome of this translational study before the phase II clinical trial is ended. All institutions included patients in the translational study on the prognostic role of CTCs. The translational study was coordinated in the Department of Otorhinolaryngology, University Hospital Jena, Germany. The protocol was centrally approved by the ethics committee for human research at the Medical Faculty, Friedrich-Schiller-University Jena, and adopted by the ethics committee of all study centers. All patients provided written informed consent before registration. Patients were included from February 2010 to May 2012 and have been observed until January 2014 or death.

Patient eligibility {#sec007}
-------------------

Patients aged ≥18 and ≤80 years were eligible for inclusion if a histologically confirmed resectable squamous cell carcinoma of the oral cavity (excluding the lip), or of the oropharynx had been diagnosed. Tumors were judged resectable when an R0 resection was likely to be achieved. Tumors were included if they were classified as any cTcN2M0, any cTcN3M0, cT3 and cN0-1M0, cT4 and cN0-1M0 (International Union Against Cancer). Furthermore, inclusion required a Karnofsky Index ≥70% without high anesthetic risk. Adequate pulmonary, cardiac, bone marrow, hepatic and renal functions were mandatory. Exclusion criteria were distant metastatic disease; a life expectancy of \<3 months; pregnancy; previous cancer disease within 5 years of study entry. Furthermore, patients were not entered in case of serious concomitant diseases or serious medical conditions; previous treatment with chemotherapy, radiotherapy or surgery for head and neck cancer; or any social situations that would have limited the compliance with study requirements. Concurrent treatments with other experimental drugs or participation in another clinical trial with any investigational drug within 30 days before study screening were also not allowed.

Study treatment {#sec008}
---------------

TISOC-1 started with a split-dose IC containing a combination of docetaxel (Taxotere, Sanofi-Aventis), cisplatin and 5-fluorouracil (split TPF). The safety and feasibility of the split TPF regime was proven in preceding phase I trial \[[@pone.0132901.ref009]\]. According to the results of the phase I study, the phase II study was conducted with a dose of 30 mg/m^2^ docetaxel plus 40 mg/m^2^ cisplatin and 2000 mg/m^2^ fluorouracil per week. Each chemotherapy cycle lasted 3 weeks. Chemotherapy was applied with usual premedication, appropriate antiemetics and intravenous hydration. Chemotherapy was given on days 1, 8 (cycle 1), and for responders (see below) further on day 22, 29 (cycle 2), and 43, 50 (cycle 3). Tumor response was evaluated on day 21 using a clinical examination with endoscopy of the primary tumor. Additionally, a CT or MRI of the neck with tumor volumetry was performed. Tumor response to chemotherapy was defined by the RECIST criteria and as a reduction of the tumor volume ≥ 30% \[[@pone.0132901.ref012]\]. Complete remission (CR) was defined as complete disappearance of primary tumor and neck metastasis. Partial response (PR) was defined as mentioned above but without complete disappearance. Progressive disease (PD) was defined as enlargement of tumor volume ≥ 20% or new tumor manifestations. Stable disease (SD) was fulfilled for tumors with enlargement \<20% to reduction \< 30%. Responders were patients with CR or PR. All responders were assigned to treatment arm B and received two more cycles of split-TPF, i.e. responders underwent surgery after three cycles of IC. Non-responders were assigned to treatment arm A and underwent surgery after one cycle of IC. Treatment cycles were repeated if the absolute neutrophil count (ANC) was ≥ 1.000/mm3, platelet count was ≥ 80.000/mm3, neurotoxicity ≤ grade 1, hand-foot-syndrome ≤ grade 1, and adequate kidney and liver function. If these criteria had not been recovered after a 2-week delay, chemotherapy was continued with a 70% reduction after recovery of the blood parameters. Surgery was performed within the original tumor margins prior to ICT. Standard histopathology was performed. p16 IHC staining was the surrogate marker for human papillomavirus (HPV). All p16 positive tumors were also tested for HPV DNA by PCR as described previously \[[@pone.0132901.ref013]\]. More details on the study protocol, postoperative treatment and evaluations were published recently \[[@pone.0132901.ref009]\].

Detection of CTCs {#sec009}
-----------------

CTCs were detected as previously reported \[[@pone.0132901.ref014]\]. Briefly, 7.5ml of blood anticoagulated with EDTA were drawn before starting the treatment with the first cycle of IC (baseline), before second and third cycle of IC, before surgery, before postoperative radio(chemo)therapy and at the end of treatment. Concerning the prognostic role of CTCs, the absolute amount of CTCs at baseline, every increase or decrease between each step of the treatment, and the highest value of CTCs of all measurements during the treatment (maximal CTC values) were analyzed. 1ml of each blood sample was lysed with ammonium chloride using 10 ml of erythrocyte lysis solution (Qiagen, Hilden, Germany) for 10 min at room temperature spun down at 700×g and re-diluted in 1 ml of PBS (phosphate-buffered saline) pH 7.4. For detection of CTCs, white cells from the sediment were subject to the MAINTRAC analysis, diluting the pellet in 500 μl of phosphate-buffered saline (pH 7.4) and adding 12.5 μl of fluorescein isothiocyanate--conjugated mouse anti-human epithelial antibody (Miltenyi Biotec, Bergisch Gladbach, Germany) and 4 μl of 7AAD (Sigma Aldrich, St.Louis, MO, USA), (50μg/ml) simultaneously for 15 minutes in the dark. Analysis of red and green fluorescence of the cells was performed using an Olympus Scan\^R screening station which allows automated image acquisition and data analysis enabling relocation of cells for visual examination of vital epithelial cells as extensively described in a previous study \[[@pone.0132901.ref015]\]. A defined volume of the cell suspension was applied to each well of a microtiter plate and scanning was performed on the well area. Cells were detected in transmitted light, and red and green fluorescence was recorded. The epithelial cells selected by their green fluorescence were relocated and analyzed for vitality. Only vital cells were counted. CTCs were calculated per ml. It should be emphasized that the expression of anti-Human Epithelial Specific Antigen (ESA or epithelial cell adhesion molecule \[EpCAM\]) on the cell surface is not a proof that these cells are tumor cells. Although we have previously shown that EpCAM is not expressed on the surface of hematopoietic cells \[[@pone.0132901.ref016]\], this does not preclude that normal epithelial cells which have been disseminated into blood are detected by this approach.

Statistical Analysis {#sec010}
--------------------

Statistical analyses were performed using IBM SPSS version 21.0 statistical software for Windows (Chicago, Illinois, USA). To compare tumor characteristics or other parameters to the amount of detected CTCs at several time points of treatment or to compare other parameters, Pearson's chi-square test was used. If necessary, the numeric CTC parameters were dichotomized to categorical data using median values as separators: To analyze the role of the number of CTCs at baseline, the study sample was divided into two groups (smaller the median value versus greater the median value of CTC at baseline). To analyze the role of the maximal number of CTCs during the course of therapy, the study sample was also divided into two groups (smaller the median value versus greater the median of the maximal number of CTC during the whole course of treatment). Unifactorial analysis of variance (ANOVA) with post-hoc Bonferroni correction was used to compare CTCs amounts at the different time points. Recurrence-free survival (RFS) and overall survival (OS) were calculated by the Kaplan-Meier method and differences of survival were compared by the log-rank test. RFS was defined as the elapsed time between the date of the first CTC examination at baseline prior to treatment and the date of tumor recurrence, or the last follow-up (if no death was observed during the follow-up period). OS was defined as the elapsed time between the date of the first CTC examination at baseline prior to treatment and either the date of death or the last follow-up (if death was not observed during the follow-up period). Multivariable analysis was performed using the Cox proportional hazards model including significant parameters from the log-rank tests to estimate the hazard ratio (HR) with a confidence interval (CI) of 95% for RFS and OS. For all statistical tests, significance was two-sided and set to p \< 0.05.

Results {#sec011}
=======

Patient's, tumor and treatment characteristics {#sec012}
----------------------------------------------

Clinicopathologic characteristics and treatment characteristics are summarized in [Table 1](#pone.0132901.t001){ref-type="table"} and [Table 2](#pone.0132901.t002){ref-type="table"}. Most patients were male (83%). Median age was 58 years. The primary tumor was localized in the oral cavity in 15 patients (38%) and in the oropharynx in 25 patients (63%). The tumors of nineteen patients were HPV positive. Thirty-eight patients (95%) were clinically classified before treatment according to UICC stage IV and two patients (5%) as UICC stage III. Due to the tumor response after the first cycle of IC, 15 patients (38%) were treated in treatment arm A and 35 patients (63%) in treatment arm B. Surgery of the primary tumor was performed in all patients. All but one patient received a bilateral neck dissection, the one patient unilateral neck dissection. Histopathology revealed a complete remission of the primary tumor (ypT0) in 15 patients (38%) and complete remission of the neck metastases (ypN0) in 14 patients (35%). This led to a complete pathologic response in 8 patients (20%) and to a partial pathologic response in 24 patients (60%). All but one patient (96% of the arm) in treatment arm B revealed a complete or partial pathologic response, whereas in treatment arm A no patients showed a complete pathologic response and only 8 patients (53% of the arm) showed a partial pathologic response, i.e. the pathologic response to IC was significantly better in treatment arm B (p = 0.003). The most frequent postoperative treatment was radiotherapy (63%), followed by radiochemotherapy (30%), and radioimmunotherapy with cetuximab (18%).

10.1371/journal.pone.0132901.t001

###### Clinicopathologic characteristics.

![](pone.0132901.t001){#pone.0132901.t001g}

  Parameter               Frequency (N)   \%
  ----------------------- --------------- ---------------
  Total number of cases   40              100
  Gender                                  
      Male                33              83
      Female              7               18
  Tumor site                              
      Oral cavity         15              38
      Oropharynx          25              63
  cT stage                                
      T2                  15              38
      T3                  15              38
      T4a                 10              25
  cN stage                                
      N0                  3               8
      N1                  0               0
      N2                  35              87
      N3                  2               5
  cM stage                                
      M0                  42              100
      M1                  0               0
  yT stage                                
      ypT0                15              38
      ypT1                10              25
      ypT2                4               10
      ypT3                6               15
      ypT4                5               13
  ypN stage                               
      ypN0                14              35
      ypN1                6               15
      ypN2                20              60
                          Mean±SD         Median, range
  Age                     58±8            58, 44--73

10.1371/journal.pone.0132901.t002

###### Treatment characteristics.

![](pone.0132901.t002){#pone.0132901.t002g}

  Parameter                                       Frequency (N)   \%
  ----------------------------------------------- --------------- -----
  Total number of cases                           40              100
  Treatment arm                                                   
      A                                           15              38
      B                                           25              63
  Cycles of induction chemotherapy                                
      1                                           15              38
      2                                           1               3
      3                                           24              60
  Pathologic response to induction chemotherapy                   
      Complete response (CR)                      8               20
      Partial response (PR)                       24              60
      Stable disease (SD)                         6               15
      Progressive disease (PD)                    2               5
  Surgery[\*](#t002fn001){ref-type="table-fn"}                    
      Yes                                         40              100
      No                                          0               0
  Postoperative radio(chemo)therapy                               
      Radiotherapy                                25              63
      Radiochemotherapy                           12              30
      Radioimmunotherapy                          3               18

\*all surgeries were performed R0.

Circulating tumor cells (CTCs) {#sec013}
------------------------------

Only eight patients (20%) did not have any CTCs at baseline prior to treatment. The median number of CTCs at baseline was 3295/ml. On average, CTCs decreased during IC, but increased after surgery and finally reached values comparable to baseline ([Fig 1](#pone.0132901.g001){ref-type="fig"}). There was a significant increase of CTCs before postoperative radiotherapy compared to baseline before 1^st^ cycle of IC (p = 0.011), 2^nd^ cycle of IC (p = 0.001), 3^rd^ cycle of IC (p = 0.004), and before surgery (p = 0.002), but not compared to the end of therapy (p = 0.118). Median maximal CTC number during treatment was 5005 CTCs/ml. After treatment only one patient (3%) did not have any CTCs. More data on CTCs during the study treatment are presented in [Table 3](#pone.0132901.t003){ref-type="table"}. Higher (\>median) CTCs at baseline was associated to higher (\>median) maximal CTCs during therapy (p = 0.023; [S1 Table](#pone.0132901.s001){ref-type="supplementary-material"}). Higher (\>median) CTCs at baseline was also associated to recurrence (p = 0.014). Higher (\>median) maximal CTCs during therapy was more frequently observed in tumors of the oral cavity (p = 0.022) and related to higher risk of death during follow-up (p = 0.028).

![Number of circulating tumor cells per ml blood (CTCs/ml; mean ± standard deviation) before start of the treatment, during induction chemotherapy (IC), before surgery, before postoperative radiotherapy (PORT; ± chemotherapy or cetuximab), and at the end of treatment.\
Significant increase of CTCs before postoperative radiotherapy compared to baseline before 1^st^ cycle of IC (\*; p = 0.011), 2^nd^ cycle of IC (\*\*; p = 0.001), 3^rd^ cycle of IC (\*\*\*; p = 0.004), and before surgery (\*\*\*\*; p = 0.002), but not compared to the end of therapy (^\#^; p = 0.118).](pone.0132901.g001){#pone.0132901.g001}

10.1371/journal.pone.0132901.t003

###### Circulating tumor cells (CTCs) during TISOC1 treatment.

![](pone.0132901.t003){#pone.0132901.t003g}

  Parameter                                                        Frequency (N)   \%
  ---------------------------------------------------------------- --------------- -------------------
  Total number of cases                                            40              100
  No CTCs at baseline                                              8               20%
  No CTCs at the end of therapy                                    1               3%
                                                                   Mean±SD         Median, range
  CTCs at baseline (CTCs/ml)                                       5266±10419      3295, 0--55650
  CTCs before second cycle of neoadjuvant chemotherapy (CTCs/ml)   1241±2032       610, 0--6350
  CTCs before third cycle of neoadjuvant chemotherapy (CTCs/ml)    382±644         0, 0--1710
  CTCs before surgery (CTCs/ml)                                    4370±8229       853, 0--38670
  CTCs before postoperative radiotherapy(CTCs/ml)                  13991±9875      11600, 490--29620
  CTCs, at the end of therapy (CTCs/ml)                            6654± 5864      5370, 0--19640
  CTCs, maximal (CTCs/ml)                                          9286±11298      5005, 0--55650

Recurrence-free survival (RFS) and overall survival (OS) {#sec014}
--------------------------------------------------------

The median follow-up time of all patients was 24.7 months (mean: 23.1±9.6 months). The median follow-up time of all patients alive at the end of the observation period was 29.8 months (mean: 26.1±8.6 months). No recurrence was observed in 32 patients (80%). Eight patients (20%) developed a recurrence. Thirty patients (75%) were alive and ten patients (25%) were dead at the end of the observation period.

Overall, mean RFS was 32.4 months (95%CI: 29.0--35.8). 2-year RFS rate and 3-year RFS rate were 78.4% and 74.3%, respectively. Mean OS was 31.3 months (95%CI: 27.8--35.0). 2-year OS rate and 3-year OS rate were 75.1% and 70.1%, respectively. The results of the log-rank test are shown in [Table 4](#pone.0132901.t004){ref-type="table"}. Patients in treatment arm A had a significantly lower RFS and OS than patients in arm B (p = 0.025 and p = 0.025, respectively; [Fig 2A and 2C](#pone.0132901.g002){ref-type="fig"}). Patients with CTCs at baseline \>median value had significantly lower RFS than patients with CTCs at baseline \<median value (p = 0.025; [Fig 2B](#pone.0132901.g002){ref-type="fig"}). Furthermore, patients with maximal CTCs values \>median during the complete course of therapy had a significantly lower OS than patients with values \<median (p = 0.049; [Fig 2D](#pone.0132901.g002){ref-type="fig"}). No other factors had a significant influence on RFS or OS in the univariate analysis. Finally, the multivariate analysis revealed that the treatment arm and maximal CTCs during the time course of therapy both were independent prognostic risk factors for OS ([Table 5](#pone.0132901.t005){ref-type="table"}). OS was significantly lower for treatment arm A (Hazard ration \[HR\] = 5.758; CI: 1.503--22.059). For patients with maximal CTCs during treatment higher than the median value, OS was also significantly lower (HR = 6.151; CI: 1.244--30.420).

![Kaplan-Meier curves on recurrence-free survival (A, B) and overall survival (C, D) according to therapy arm (A, C), circulating tumor cells (CTCs) at baseline (B), and maximal amount of CTCs during the treatment.](pone.0132901.g002){#pone.0132901.g002}

10.1371/journal.pone.0132901.t004

###### Univariate analysis (log-rank test) of negative prognostic parameters influencing recurrence-free survival (RFS) and overall survival (OS).

![](pone.0132901.t004){#pone.0132901.t004g}

  Parameter                               RFS         OS
  --------------------------------------- ----------- -----------
  Gender, female                          0.219       0.951
  Age (≥median of 58 years)               0.890       0.877
  Localization, oral cavity               0.101       0.100
  cT Stage (advanced, T3/T4)              0.409       0.591
  cN Stage (N+)                           0.675       0.963
  HPV status (HPV negative)               0.270       0.791
  Pathological response (not CR)          0.326       0.066
  Therapy arm (Arm A)                     **0.025**   **0.025**
  CTCs at baseline, \>median              **0.025**   0.951
  CTCs maximal during therapy, \>median   0.355       **0.049**
  CTCs increase after IC                  0.660       0.437
  CTCs increase after surgery             0.367       0.188
  CTCs increase after radiotherapy        0.385       0.787

CR = complete response; IC = induction chemotherapy

10.1371/journal.pone.0132901.t005

###### Multivariable Cox regression of negative risk factors for recurrence-free survival (RFS) and overall survival (OS).

![](pone.0132901.t005){#pone.0132901.t005g}

  Factor                        HR[\*](#t005fn001){ref-type="table-fn"}   95%CI             p
  ------------------ ---------- ----------------------------------------- ----------------- -----------
  **RFS**                                                                                   
  Therapy arm        B          1                                         Reference value   0.101
                     A          4.541                                     0.744--27.716     
  CTCs at baseline   \<median   1                                         Reference value   0.950
                     \>median   0                                         0--1.509E+162     
  **OS**                                                                                    
  Therapy arm        B          1                                         Reference value   **0.011**
                     A          5.758                                     1.503--22.059     
  CTCs maximal       \<median   1                                         Reference value   **0.026**
                     \>median   6.151                                     1.244--30.420     

\*HR = Hazard Ratio

Discussion {#sec015}
==========

Compared to other cancer entities, the impact of CTCs in SCCHN patients has not yet been extensively documented and is not applied in clinical routine \[[@pone.0132901.ref017]\]. It is known that the stage of disease is correlated to the CTC levels. In untreated local advanced SCCHN 12.5--100% of patients CTCs are detected depending on the detection method and included tumor stages \[[@pone.0132901.ref018]--[@pone.0132901.ref021]\].

The number of detected CTCs depends on the detection method \[[@pone.0132901.ref017], [@pone.0132901.ref020]\]. The FDA-approved automated CellSearch System (Veridex, New Jersey, USA) uses magnetically labeled EpCAM-specific antibodies to separate the adhering CTCs in a magnetic field. Using this approach, median CTCs numbers of 0--2 CTCs/7.5ml in locally advanced SCCHN are reported \[[@pone.0132901.ref022], [@pone.0132901.ref023]\]. Using a flow cytometric assay for the detection of CTCs, the number of CTCs ranged between 1-4/3.75 ml in locally advanced SCCHN \[[@pone.0132901.ref018], [@pone.0132901.ref021]\]. Using a multiparameter analysis based on a negative depletion enrichment methodology, baseline values of 0--3969 CTCs/ml are reported for locally advanced SCCHN \[[@pone.0132901.ref003]\].Using a negative selection method for effective leukocyte depletion and enhanced detection of viable EpCAM positive and negative CTCs, the number are in the same scale with 0--3440 CTCs/ml \[[@pone.0132901.ref024]\]. The method used in the present study is characterized by its non-dissipative approach and gives CTCs numbers in the same scale. The scanning microscope reliably detects the EpCAM positive events among the other blood cells without any additional enrichment step and allows visual inspection of the vital cells excluding the viability marker 7AAD. Repeated preparations of the same blood samples gave less than 10% variation in CTCs numbers and thus highly reproducible results. Using conventional blood count tubes and shipping at ambient temperature allowed easy sampling in a multicenter setting. Under these conditions samples showed \>95% cell viability. Using EpCAM as marker does not preclude that normal epithelial cells which have been disseminated into blood are detected by this approach. However, since circulating epithelial cells were detected in 80% of patients with non-metastatic SCCHN and their number correlated with disease outcome the cells detected could be subsumed as CTCs.

It is important to note that OSCC does not represent a homogenous entity of HNSCC. In contrast to tumors of the oral cavity, oropharyngeal tumors, especially tonsil cancer, often is associated to human papillomaviruses (HPV) infection. This has influence on the carcinogenesis and normally also on the prognosis of the patients \[[@pone.0132901.ref025]\]. Interestingly, tumor localization and HPV status did not have a significant impact on OS under the complex treatment concept of present study. In the present study, response to IC was the most significant prognosticator for OS as it was shown by others when using IC in head and neck organ preservation protocols \[[@pone.0132901.ref026], [@pone.0132901.ref027]\]. A high number of CTCs during the course of the treatment was the other independent negative prognosticator for OS. Hence, the present study showed for the first time the impact of detection of changes of the number of CTCs during OSCC treatment which included IC. So far there was only some evidence that detection of CTCs at baseline correlates with worse RFS and OS in locally advanced HNSCC using surgery and postoperative radiotherapy or concurrent radiochemotherapy \[[@pone.0132901.ref021], [@pone.0132901.ref023], [@pone.0132901.ref028]\].

Looking on the time course of the CTCs detection during therapy, CTCs decreased on average during IC, re-increased before surgery, re-increased to maximal values after surgery and re-decrease after postoperative radiotherapy. So far not much is known about the time course of CTC detection during HNSCC therapy and its role as marker for treatment response. Most studies include heterogeneous groups of HNSCC or have a small sample size \[[@pone.0132901.ref017]\]. It has been shown that CTCs decrease after chemoradiation \[[@pone.0132901.ref022]\]. The data on the effect of surgery on CTCs is contradictory: CTCs seem to be significantly present after surgery \[[@pone.0132901.ref029]\], may even increase after surgical manipulation of head and neck tumors \[[@pone.0132901.ref030]\], but a decrease of CTCs after tumor resection has also be reported \[[@pone.0132901.ref018]\]. An increase of CTCs after tumor resection has also be reported for instance for esophageal cancer, lung cancer, or rectal cancer \[[@pone.0132901.ref031]--[@pone.0132901.ref033]\]. It must kept in mind for the present study, that surgery was performed after IC and that 20% of patients had a complete pathologic response, i.e. no more vital tumor cells were observed by standard histopathological methods in primary tumor area and the neck. Despite of this, CTCs increased in most of these patients after surgery. Paradoxically, the relative increase of CTCs after surgery had no negative prognostic impact on RFS or OS. In a recent study by Tinhofer et al. \[[@pone.0132901.ref029]\], the detection of CTCs after surgery and before adjuvant chemoradiation in patients with oropharyngeal cancer (in contrast to other HNSCC sites) even was associated per trend with improved disease-free survival. The reason is unclear and need to be elucidated in further studies with larger study samples.

It should not be neglected that IC is not considered to be part of standard therapy for locally advanced OSCC. Hence, patients should be carefully selected when considering IC. Recently, first predictive biomarkers for the response to IC like the TP53 mutation status, Cyclin D1 (CCND1) expression, or Annexin A1 expression have been reported \[[@pone.0132901.ref034]--[@pone.0132901.ref036]\]. If CTCs may also represent a potential predictive marker has to be explored in more detail in future studies.

In conclusion, we established the detection of CTCs as an independent prognostic markers for OSCC when treated by TPF induction chemotherapy, surgery, and postoperative (chemo)radiation. The method used allows a reliable collection of CTCs at different time points during therapy even in multicenter trial settings. Therefore, it seems to be feasible to validate our findings, and especially to examine more profoundly the role of CTCs as a marker for therapy response during IC, in a future larger trial.

Supporting Information {#sec016}
======================

###### Univariate analysis of the association between CTC at baseline and maximal CTC during therapy, respectively, to other clinicopathologic characteristics.
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